This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on participants who have diabetic kidney disease.
The aim of the study is to see how safe and effective the study drugs are.
The study is looking at several other research questions, including:
* What side effects may happen from taking the study drug * How much study drug is in the blood at different times
Medical history of type 2 diabetes and receiving medical therapy or lifestyle interventions for glucose management
Hemoglobin A1C (HbA1c) of 6.5 to 10% at screening
eGFR 30 to 90 mL/min/1.73 m² using 2021 Chronic Kidney Disease-Epidemiology Collaboration-Estimated Glomerular Filtration Rate using Creatinine and Cystatin C (CKD-EPI eGFRcr-cys) equation at screening
Albuminuria: Urine Albumin to Creatinine Ratio (UACR) of 500 to 5000 mg/g at screening
Known medical history or clinical evidence indicative of non-diabetic renal disease
Renal disease that required treatment with systemic immunosuppressive therapy (prior or current), or a history of end-stage kidney disease requiring treatment with chronic dialysis or kidney transplantation
Medically unstable as assessed by the investigator or hospitalization (ie, >24 hours) within 30 days of the screening visit
Parallel
ALN-ANG3
DrugAdministered per the protocol
Evinacumab
DrugNo longer being administered
Placebo
DrugAdministered per the protocol
Percent Change in Urine Albumin to Creatinine Ratio (UACR)
Change in Estimated Glomerular Filtration Rate (eGFR)
Change in Total Cholesterol
Change in Low-Density Lipoprotein-Cholesterol (LDL-C)
Change in High-Density Lipoprotein-Cholesterol (HDL-C)
Click on the lead sponsor to view all of their trials.
